Sulfarotene Inhibits Colorectal Cancer via Mitigating Natural-Killer-Cell-Induced Stemness

Keshu Hu,Yu Dong,Jiayu Zhang,Mengling Liu,Xun Sun,Xin Cao,Pengfei Zhang,Tianshu Liu

DOI: https://doi.org/10.3390/ph17030387

IF: 4.6

2024-03-19

Pharmaceuticals

Abstract:Tumor cell stemness stands out as a pivotal factor driving tumor recurrence or metastasis and significantly contributes to the mortality of patients with colorectal cancer (CRC). Recent research has unveiled a link between immune-active cells and the induction of tumor cell stemness, ultimately leading to heightened resistance to treatment. In this study, stemness in CRC cell lines was assessed after co-culture with natural killer (NK) cells, both with and without sulfarotene administration. Furthermore, a CRC xenograft model was utilized to scrutinize the in vivo efficacy of sulfarotene in overcoming stemness induced by NK cell activation. As a result, CRC cells exhibited significant stemness after NK cell co-culture, as evidenced by the upregulation of several stemness markers associated with cancer stem cells. Moreover, these cells demonstrated remarkable resistance to commonly used chemotherapy agents for CRC, such as oxaliplatin and irinotecan. Importantly, sulfarotene effectively reversed the altered stemness of CRC cells in both in vitro and in vivo assays. In conclusion, sulfarotene emerges as a promising therapeutic strategy for overcoming colorectal cancer resistance to NK cells by effectively inhibiting stemness remodeling. This study underscores the potential of sulfarotene in augmenting NK-cell-mediated immune surveillance, proposing a novel immunotherapeutic approach against colorectal cancer.

pharmacology & pharmacy,chemistry, medicinal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: Natural killer cells (NK cells) will promote the stemness characteristics of colorectal cancer (CRC) cells after activation, causing these cells to become resistant to chemotherapeutic drugs. Researchers hope to use a newly synthesized retinol named Sulfarotene to inhibit this enhancement of stemness characteristics caused by NK cell activation, thereby improving the efficacy of colorectal cancer treatment.

Specifically, the paper explores the following points:
1. **The influence of NK cells on the stemness of CRC cells**: The study found that after co - culturing with NK cells, CRC cells showed significant stemness characteristics, such as increased expression of the proliferation marker KI67 and the stemness markers CD90, CD44, LGR5 and NANOG, indicating that activated NK cells can be a powerful factor driving the stemness characteristics of CRC cells.
2. **The change in the sensitivity of CRC cells to drugs**: The study showed that CRC cells with stemness characteristics have reduced sensitivity to commonly used chemotherapeutic drugs such as irinotecan and oxaliplatin, but increased sensitivity to Sulfarotene.
3. **The functional state of NK cells in the CRC tumor microenvironment**: Through single - cell RNA sequencing analysis, it was found that NK cells from CRC tissues showed an immunosuppressive phenotype and exhaustion characteristics, which contribute to the formation of an immunotolerant tumor microenvironment.
4. **The combined effect of Sulfarotene and anti - TIGIT immunotherapy**: The study found that Sulfarotene can further enhance the effect of anti - TIGIT immunotherapy, reduce the volume and weight of CRC tumors, and reverse the enhancement of CRC cell stemness characteristics caused by anti - TIGIT immunotherapy.

In conclusion, this paper aims to improve the treatment effect of colorectal cancer by using Sulfarotene to inhibit the enhancement of CRC cell stemness characteristics caused by NK cell activation.